DiaSys successfully introduced Total bile acids 21 FS to determine total bile acids (TBA) in serum. Now, without altering the reagent composition and the highly sensitive enzymatic cycling method, the scope of the test has been expanded to detect TBA in human stool samples.
TBA determination in stool plays a major role to diagnose gastrointestinal tract disorders, such as irritable bowel syndrome with diarrhea (IBS-D), bile acid diarrhea (BAD) or Crohn’s disease. Approximately 25 – 50% of patients with IBS-D display increased total fecal bile acids. Furthermore, BAD is a common cause of chronic unexplained diarrhea.
Even though IBS-D and BAD occur worldwide, the gold standard diagnosis method (75SeHCAT test) is not licensed in some countries and not common in standard clinical laboratories. The time span for this test is seven days, which is inconveniently time-consuming. Moreover, patients undergoing this test have to ingest a radioactive substance, which is another disadvantage of this method. Alternative methods, such as LC-MS or GC-MS, are technically complex.
Total bile acids 21 FS is conveniently applicable on all clinical chemistry analyzers. The liquid-stable, ready-to-use DiaSys reagent has a wide measuring range (up to 130 µmol/L), good precision and long onboard and calibration stability. It shows good reproducibility and minimum interference from endogenous substances that may interfere.